MXPA05003694A - Nuevo proceso para la sintesis ivabradina y sales de adicion de la misma con un acido farmaceuticamente aceptable. - Google Patents

Nuevo proceso para la sintesis ivabradina y sales de adicion de la misma con un acido farmaceuticamente aceptable.

Info

Publication number
MXPA05003694A
MXPA05003694A MXPA05003694A MXPA05003694A MXPA05003694A MX PA05003694 A MXPA05003694 A MX PA05003694A MX PA05003694 A MXPA05003694 A MX PA05003694A MX PA05003694 A MXPA05003694 A MX PA05003694A MX PA05003694 A MXPA05003694 A MX PA05003694A
Authority
MX
Mexico
Prior art keywords
methyl
ivabradine
synthesis
acid addition
addition salts
Prior art date
Application number
MXPA05003694A
Other languages
English (en)
Inventor
Gerard Damien
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34941959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05003694(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MXPA05003694A publication Critical patent/MXPA05003694A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01C—CONSTRUCTION OF, OR SURFACES FOR, ROADS, SPORTS GROUNDS, OR THE LIKE; MACHINES OR AUXILIARY TOOLS FOR CONSTRUCTION OR REPAIR
    • E01C11/00—Details of pavings
    • E01C11/16—Reinforcements
    • E01C11/165—Reinforcements particularly for bituminous or rubber- or plastic-bound pavings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Structural Engineering (AREA)
  • Architecture (AREA)
  • Civil Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion describe un proceso para la sintesis de ivabradina de formula (I): (ver formula I) las sales de adicion de la misma con un acido farmaceuticamente aceptable, y los hidratos de la misma. Tambien describe la forma cristalina ( del clorhidrato de ivabradina. Medicamentos.
MXPA05003694A 2004-04-13 2005-04-07 Nuevo proceso para la sintesis ivabradina y sales de adicion de la misma con un acido farmaceuticamente aceptable. MXPA05003694A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0403830A FR2868777B1 (fr) 2004-04-13 2004-04-13 Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable

Publications (1)

Publication Number Publication Date
MXPA05003694A true MXPA05003694A (es) 2006-01-24

Family

ID=34941959

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05003694A MXPA05003694A (es) 2004-04-13 2005-04-07 Nuevo proceso para la sintesis ivabradina y sales de adicion de la misma con un acido farmaceuticamente aceptable.

Country Status (43)

Country Link
US (2) US7176197B2 (es)
EP (1) EP1589005B1 (es)
JP (2) JP4515934B2 (es)
KR (1) KR100677019B1 (es)
CN (1) CN1305856C (es)
AP (1) AP1821A (es)
AR (1) AR047745A1 (es)
AT (1) ATE358123T1 (es)
AU (1) AU2005200861B2 (es)
BR (1) BRPI0500585B8 (es)
CA (1) CA2496723C (es)
CO (1) CO5670092A1 (es)
CR (2) CR7691A (es)
CU (1) CU23465B7 (es)
CY (1) CY1106597T1 (es)
DE (1) DE602005000765T2 (es)
DK (1) DK1589005T3 (es)
EA (1) EA007745B1 (es)
EC (1) ECSP055610A (es)
ES (1) ES2285651T3 (es)
FR (1) FR2868777B1 (es)
GE (1) GEP20074138B (es)
HK (1) HK1080362B (es)
HR (1) HRP20070246T5 (es)
IL (1) IL167013A (es)
MA (1) MA27600A1 (es)
ME (1) ME01396B (es)
MX (1) MXPA05003694A (es)
MY (1) MY141194A (es)
NI (1) NI200500031A (es)
NO (1) NO329807B1 (es)
NZ (1) NZ538326A (es)
OA (1) OA12913A (es)
PL (1) PL1589005T3 (es)
PT (1) PT1589005E (es)
RS (1) RS50511B (es)
SA (1) SA05260016B1 (es)
SG (1) SG116575A1 (es)
SI (1) SI1589005T1 (es)
UA (1) UA80834C2 (es)
UY (1) UY28759A1 (es)
WO (1) WO2005110993A1 (es)
ZA (1) ZA200501466B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868775B1 (fr) * 2004-04-13 2008-04-11 Servier Lab Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2868776B1 (fr) * 2004-04-13 2008-04-18 Servier Lab Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
ATE544754T1 (de) 2006-11-30 2012-02-15 Cadila Healthcare Ltd Verfahren zur herstellung von ivabradinhydrochlorid
WO2008125006A1 (fr) * 2007-04-12 2008-10-23 Utopharm (Shanghai) Co., Ltd Procédés de préparation du chlorhydrate d'ivabradine et de sa forme cristalline stable
PT2471780E (pt) * 2007-05-30 2015-02-24 Ind Swift Lab Ltd Sais oxalato de ivabradina cristalinos e seus polimorfos
SI22750A (sl) * 2008-04-07 2009-10-31 Krka D.D. Ivabradin hidrobromid
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2933975B1 (fr) 2008-07-17 2011-02-18 Servier Lab Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
FR2935381B1 (fr) 2008-08-29 2010-12-17 Servier Lab Nouveau procede de resolution des enantiomerees du (3,4-dimethoxy-bicyclo°4.2.0!octa-1,3,5-trien-7-yl)nitrile et application a la synthese de l'ivabradine
CN101723897B (zh) * 2008-10-31 2011-11-16 齐鲁制药有限公司 伊伐布雷定的合成方法
ES2402765T3 (es) * 2008-12-22 2013-05-08 Krka, D.D., Novo Mesto Procedimiento de preparación de ivabradina
FR2940287B1 (fr) * 2008-12-24 2010-12-24 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
CN101768117B (zh) * 2008-12-29 2014-05-07 北京德众万全药物技术开发有限公司 一种盐酸伊伐布雷定晶型及其制备方法
CN101768116B (zh) * 2008-12-29 2014-06-18 北京德众万全药物技术开发有限公司 一种伊伐布雷定的制备方法
FR2941695B1 (fr) * 2009-02-04 2011-02-18 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
ME00987B (me) * 2009-03-31 2012-06-20 Servier Lab Novi postupak sinteze ivabradina i njegovih soli sa farmaceutski prihvatljivom kiselinom
FR2943668B1 (fr) 2009-03-31 2011-05-06 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
HUE035588T2 (en) 2010-02-12 2018-05-28 Krka D D Novo Mesto Form of ivabradine hydrochloride
FR2956401B1 (fr) * 2010-02-17 2012-02-03 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
WO2011104723A2 (en) * 2010-02-23 2011-09-01 Ind-Swift Laboratories Limited Acid addition salts of ivabradine and preparation thereof
HUP1000245A2 (en) * 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
US8900605B2 (en) 2010-06-14 2014-12-02 Ratiopharm Gmbh Solid ivabradine-containing composition
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
FR2971507B1 (fr) * 2011-02-14 2013-01-18 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
CN102304088B (zh) * 2011-07-07 2013-06-19 石药集团欧意药业有限公司 一种伊伐布雷定化合物、制备方法及其药物组合物
WO2013017582A1 (en) 2011-08-02 2013-02-07 Sandoz Ag Acetone solvate of ivabradine hydrochloride
EP2773621B1 (en) 2011-11-04 2015-12-30 Synthon BV A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (en) * 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
WO2013102919A1 (en) 2011-11-14 2013-07-11 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
FR2984320B1 (fr) * 2011-12-20 2013-11-29 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2984319B1 (fr) 2011-12-20 2013-12-27 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2986804A1 (fr) * 2012-02-09 2013-08-16 Servier Lab Procede de synthese enzymatique de l'acide (7s) 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene 7-carboxylique ou de ses esters, et application a la synthese de l'ivabradine et de ses sels
FR2988720B1 (fr) * 2012-03-27 2014-03-14 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2993561B1 (fr) * 2012-07-17 2014-10-31 Servier Lab Procede de synthese enzymatique de la (7s)-1-(3,4-dimethoxy bicyclo[4.2.0]octa-1,3,5-triene 7-yl) n-methyl methanamine, et application a la synthese de l'ivabradine et de ses sels
CN103848789B (zh) * 2012-11-29 2016-05-18 江苏恒瑞医药股份有限公司 一种伊伐布雷定的制备方法
CN103012268B (zh) * 2013-01-05 2015-02-25 江苏宇田生物医药科技有限公司 一种伊伐布雷定制备方法
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
PL2781509T5 (pl) 2013-03-19 2023-09-25 Chemo Research, S.L. Nowy polimorf chlorowodorku iwabradyny i sposób jego otrzymywania
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
ITMI20130684A1 (it) * 2013-04-24 2014-10-25 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
CZ305096B6 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
MX363389B (es) 2013-12-12 2019-03-20 Synthon Bv Composicion farmaceutica que comprende ivabradina amorfa.
CN103864690B (zh) * 2014-01-06 2016-09-14 北京莱瑞森医药科技有限公司 伊伐布雷定盐酸盐的s晶型、其制备方法和药物组合物
SI2774606T1 (sl) 2014-02-14 2019-05-31 Synthon B.V. Farmacevtski sestavek, ki obsega polimorf IV ivabradin hidroklorida
CN103880748B (zh) * 2014-04-03 2015-09-16 南京正大天晴制药有限公司 一种盐酸伊伐布雷定结构类似物及其制备方法和应用
CZ305436B6 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2016102423A1 (en) 2014-12-22 2016-06-30 Ratiopharm Gmbh Composition comprising ivabradine in a dissolved form
EP3101010A1 (en) 2015-06-03 2016-12-07 Urquima S.A. New method for the preparation of highly pure ivabradine base and salts thereof
CN107056706B (zh) * 2015-12-21 2020-05-05 江苏恒瑞医药股份有限公司 一种用于制备盐酸伊伐布雷定α晶型的方法
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
US20230140818A1 (en) 2017-04-27 2023-05-04 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
WO2020092288A1 (en) 2018-10-30 2020-05-07 Amgen Inc. Process of making ivabradine hydrochloride drug product
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl
CN115286577B (zh) * 2022-08-25 2023-10-20 江苏永安制药有限公司 一种盐酸伊伐布雷定及其中间体的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3418270A1 (de) 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3519735A1 (de) * 1985-06-01 1986-12-04 Dr. Karl Thomae Gmbh, 7950 Biberach Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2834896B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'ivabradine
FR2868776B1 (fr) * 2004-04-13 2008-04-18 Servier Lab Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2868775B1 (fr) * 2004-04-13 2008-04-11 Servier Lab Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
US20050228177A1 (en) 2005-10-13
HK1080362A1 (en) 2006-04-28
UY28759A1 (es) 2005-12-30
NI200500031A (es) 2006-05-25
CN1305856C (zh) 2007-03-21
CY1106597T1 (el) 2012-01-25
SG116575A1 (en) 2005-11-28
HK1080362B (zh) 2007-07-20
AU2005200861B2 (en) 2010-07-15
HRP20070246T3 (en) 2007-08-31
FR2868777A1 (fr) 2005-10-14
DK1589005T3 (da) 2007-07-30
ATE358123T1 (de) 2007-04-15
CR11780A (es) 2010-12-09
AP2005003222A0 (en) 2005-03-31
CO5670092A1 (es) 2006-08-31
NO20050884L (no) 2005-10-14
PL1589005T3 (pl) 2007-07-31
AR047745A1 (es) 2006-02-15
PT1589005E (pt) 2007-06-18
CN1683341A (zh) 2005-10-19
CA2496723A1 (fr) 2005-10-13
CU23465B7 (es) 2009-12-17
DE602005000765T2 (de) 2008-01-10
US20070135411A1 (en) 2007-06-14
OA12913A (en) 2006-10-13
ES2285651T3 (es) 2007-11-16
FR2868777B1 (fr) 2006-05-26
RS50511B (sr) 2010-03-02
ECSP055610A (es) 2006-03-01
AU2005200861A1 (en) 2005-10-27
UA80834C2 (en) 2007-11-12
CR7691A (es) 2008-09-23
MA27600A1 (fr) 2005-11-01
JP2005298480A (ja) 2005-10-27
EP1589005A1 (fr) 2005-10-26
CA2496723C (fr) 2010-05-25
BRPI0500585A (pt) 2005-11-16
SA05260016B1 (ar) 2009-06-06
ME01396B (me) 2010-03-02
KR20060042116A (ko) 2006-05-12
EA200500238A1 (ru) 2005-10-27
JP2010047578A (ja) 2010-03-04
NO329807B1 (no) 2010-12-20
EP1589005B1 (fr) 2007-03-28
NO20050884D0 (no) 2005-02-18
EA007745B1 (ru) 2006-12-29
SI1589005T1 (sl) 2007-08-31
JP4848449B2 (ja) 2011-12-28
KR100677019B1 (ko) 2007-02-01
IL167013A (en) 2011-08-31
HRP20070246T5 (en) 2008-10-31
GEP20074138B (en) 2007-06-25
NZ538326A (en) 2005-11-25
US7867994B2 (en) 2011-01-11
BRPI0500585B8 (pt) 2021-05-25
WO2005110993A1 (fr) 2005-11-24
ZA200501466B (en) 2005-11-30
US7176197B2 (en) 2007-02-13
JP4515934B2 (ja) 2010-08-04
DE602005000765D1 (de) 2007-05-10
MY141194A (en) 2010-03-31
BRPI0500585B1 (pt) 2020-11-03
AP1821A (en) 2008-01-21

Similar Documents

Publication Publication Date Title
MXPA05003694A (es) Nuevo proceso para la sintesis ivabradina y sales de adicion de la misma con un acido farmaceuticamente aceptable.
AU2009245875B2 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
WO2008065681A3 (en) Process for preparation of ivabradine hydrochloride
KR100636499B1 (ko) 1,3,4,5-테트라히드로-2ｈ-3-벤즈아제핀-2-온 화합물의 합성 방법, 및 이바브라딘 및 이의 약제학적으로 허용되는 산과의 부가염의 합성에서의 용도
HUP0103417A2 (hu) Eljárás citalopram előállítására
FI78473C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1-fenyloxi-2,3,4,5-tetrahydro-3-bensazepinderivat, och vid foerfarandet anvaendbara mellanprodukter.
MA31071B1 (fr) Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et des sels d'addition a un acide pharmaceutiquement acceptable
CN100480231C (zh) 制备苯乙胺衍生物的方法
NZ579270A (en) New process for the resolution of enantiomers of 1-cyano-4,5-dimethoxy-benzocyclobutane and application in the synthesis of ivabradine
HK1148749A1 (en) Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
Zhao et al. Design, synthesis, and discovery of 3-piperazinyl-3, 4-dihydro-2 (1H)-quinolinone derivatives: a novel series of mixed dopamine D2/D4 receptor antagonists
DK2687506T3 (en) A process for the enzymatic synthesis of (7 S) -1- (3,4-dimethoxybicyclo [4.2.0] octa-1,3,5-trien-7-yl) -N-methylmethanamine and use for the synthesis of ivabradine and its salts
NZ598138A (en) Synthesis of ivabradine via cyclisation of an acetal intermediate
JP2009173672A (ja) 化合物の求核置換反応における使用
NZ616768A (en) New process for the synthesis of (2e)-3-(3,4-dimethoxyphenyl)prop-2-enenitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
Weis et al. Synthesis of new analogues of diphenylpyraline
Trout et al. Asymmetric synthesis of a potent azepanone-based inhibitor of the cysteine protease cathepsin K
AU2013237671C1 (en) New process for the synthesis of 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, and application in the synthesis of ivabradine and additional salts thereof with a pharmaceutically acceptable acid
KR101409335B1 (ko) 테트라베나진의 입체선택적 합성 방법
CN106588771A (zh) 一种盐酸贝西沙星关键中间体的制备方法
MXPA99005450A (es) Proceso para la produccion estereoselectiva de compuestos de nitro-enamina

Legal Events

Date Code Title Description
FG Grant or registration